His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia ...
Morning Overview on MSN
The FDA approved Anktiva as the first treatment for one BCG-resistant form of bladder cancer
On October 14, the U.S. Food and Drug Administration announced that Anktiva (nogapendekin alfa inbakicept-pmln), used ...
Revolution Medicines' daraxonrasib is the first drug that can broadly tackle one of the main drivers of pancreatic cancer.
Learn how personalized cancer vaccines work and what to watch for at ESMO 2026. A vaccine made from a person’s own tumor has become the first of its kind to succeed in a phase 3 trial. Full results ...
ImmunityBio (IBRX) stock fell 7.25% to $9.27 despite ANKTIVA trial results showing a 71% response rate and lasting benefits ...
Novo has long sold a separate version of oral semaglutide for diabetes under the brand name Rybelsus, which the medicine ...
The FDA has granted two Breakthrough Therapy Designations to telisotuzumab adizutecan (Temab-A, also known as ABBV-400), an ...
Daraxonrasib, a drug developed by Dana-Farber Cancer Institute, works by blocking the specific gene mutations thought to drive abnormal cell growth in pancreatic cancer. The treatment has shown so ...
The question is which platforms will actually deliver measurable impact and which will simply add another layer of complexity ...
MAMMÔ 2026 highlighted advances in breast cancer screening, ctDNA, ADCs, endocrine therapy, de-escalation and precision ...
Professor Stacey Edwards is on a mission to create a groundbreaking breast cancer treatment after her mother's death. Read ...
Intermountain Health oncologists say a new medication just approved by the U.S. Food and Drug Administration appears to be a breakthrough in the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results